Your browser is no longer supported. Please, upgrade your browser.
Nuvation Bio Inc.
Index- P/E- EPS (ttm)- Insider Own27.10% Shs Outstand412.96M Perf Week-12.63%
Market Cap2.82B Forward P/E- EPS next Y-0.66 Insider Trans0.70% Shs Float116.00M Perf Month4.01%
Income- PEG- EPS next Q-0.10 Inst Own67.20% Short Float4.09% Perf Quarter-18.79%
Sales- P/S- EPS this Y-100.00% Inst Trans410.15% Short Ratio5.07 Perf Half Y11.86%
Book/sh1.95 P/B5.85 EPS next Y-43.50% ROA- Target Price17.80 Perf Year-
Cash/sh3.34 P/C3.42 EPS next 5Y- ROE- 52W Range8.56 - 15.23 Perf YTD-2.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.08% Beta-
Dividend %- Quick Ratio83.20 Sales past 5Y- Gross Margin- 52W Low33.29% ATR0.91
Employees36 Current Ratio83.20 Sales Q/Q- Oper. Margin- RSI (14)41.51 Volatility8.24% 7.62%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.85 Prev Close11.66
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume936.12K Price11.41
Recom1.50 SMA20-13.24% SMA50-3.08% SMA2003.36% Volume797,454 Change-2.14%
Apr-06-21Initiated RBC Capital Mkts Outperform $15
Mar-08-21Initiated Wedbush Outperform $20
Mar-08-21Initiated Jefferies Buy $20
Mar-08-21Initiated Cowen Outperform
Mar-08-21Initiated BTIG Research Buy $16
Mar-08-21Initiated BMO Capital Markets Outperform $16
Jun-01-21 07:00AM  
May-26-21 07:00AM  
May-21-21 04:34PM  
May-17-21 05:00PM  
May-11-21 05:51AM  
Apr-17-21 09:36PM  
Mar-11-21 05:15PM  
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NODELMAN OLEGDirectorApr 13Buy10.2731,500323,5376,990,265Apr 13 05:55 PM
NODELMAN OLEGDirectorApr 12Buy9.49133,0001,261,8776,962,731Apr 13 05:55 PM
NODELMAN OLEGDirectorApr 09Buy10.03300,0003,009,1806,846,476Apr 13 05:55 PM
Sharp ShaliniDirectorFeb 10Option Exercise0.0025,000025,000Feb 26 07:02 PM
BRADBURY DANIELDirectorFeb 10Option Exercise0.0025,000025,000Feb 26 07:01 PM
Hasnain FaheemDirectorFeb 10Option Exercise0.0025,000025,000Feb 26 07:00 PM
COOPER GRAHAM KDirectorFeb 10Option Exercise0.0025,000025,000Feb 26 06:59 PM